

ELISA detection of SARS-CoV-2 antibodies in saliva

Melanie A. MacMullan^{*1,2}, Albina Ibrayeva^{*1,3,4}, Kylie Trettner^{1,2}, Laura Deming¹, Sudipta Das¹, Frances Tran¹, Jose Ricardo Moreno^{1,5}, Joseph G. Casian¹, Prithivi Chellamuthu¹, Jeffrey Kraft¹, Kenneth Kozak¹, Fred E. Turner¹, Vladimir I. Slepnev¹, Lydia M. Le Page¹

***These authors contributed equally to this work**

¹Curative Inc, San Dimas, CA 91773, USA, ²Mork Family Department of Chemical Engineering and Materials Science, Viterbi School of Engineering, University of Southern California, ³Eli and Edythe Broad Center for Regenerative Medicine & Stem Cell Research at USC, Department of Stem Cell Biology and Regenerative Medicine, W.M. Keck School of Medicine, ⁴Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA, ⁵Bridge Institute, Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California

Word count: Main text 1448; Methods 1167

Corresponding authors:

Vladimir I Slepnev
Curative Inc
430 S Cataract Ave
San Dimas
91773
Vlad.slepnev@curativeinc.com

Lydia M Le Page
Lydia.mlp@gmail.com

1 **Abstract**

2

3 To facilitate containment of the COVID-19 pandemic currently active in the United States and
4 across the world, options for easy, non-invasive antibody testing are required. Here we have
5 adapted a commercially available, serum-based ELISA for use with saliva samples, which will
6 enable widespread, affordable testing for patients who experienced this disease.

7

8

9 **Main text**

10

11 Following the first confirmed case of the 2019 coronavirus (COVID-19) in Wuhan, China on
12 December 2, 2019¹, cases spread both within China and worldwide, with the World Health
13 Organization declaring COVID-19 a pandemic on March 11, 2020². 89,625 cases have been
14 reported in China as of August 14 2020³. Worldwide, as of that same date, more than 20 million
15 cases and over 750,000 confirmed deaths have been reported. Approximately a quarter of these
16 cases and a fifth of these deaths have occurred in the United States, following the first known
17 case in the US reported on 19 January 2020 in Washington State⁴. The continuing, devastating
18 presence of this virus in the US makes it essential that the best tools are developed to understand
19 this disease in as great a population as possible.

20

21 Taking into account our current understanding of previous coronaviruses, it is expected that
22 patients with SARS-CoV-2 will develop antibodies against the virus. The emerging literature
23 supports this, although our understanding of the rates of seroconversion and timelines of
24 immunoglobulins M, G, and A is still developing⁵. Antibody detection is typically performed using
25 patient serum, requiring the use of trained phlebotomists and limiting the ability to test a large
26 patient population. Further, a method for self-collection of samples is needed to minimize potential

27 exposure of healthcare personnel during interaction with a patient. As seen with testing for the
28 virus, one sample type has been insufficient and testing per capita has been hugely variable
29 between countries⁶. In the US, the Centers for Disease Control and Protection now recommend
30 options of several upper respiratory tract specimen types⁷ from which to test for the virus. This
31 variety of specimen options provides greater opportunity for widespread testing, and the easiest
32 methods of sampling would enable widespread and frequent testing.

33

34 Sensitive antibody tests for other viruses have been successful in dried blood spot^{8,9} and saliva
35 samples¹⁰⁻¹². Saliva samples are particularly attractive given the ease and non-invasiveness of
36 sampling, allowing for substantial scaling of testing. Initial discussion^{13,14} and testing in small
37 sample sets indicates the potential for using saliva for SARS-CoV2 antibody testing¹⁵.

38

39 In this manuscript we hypothesized that saliva is an acceptable specimen for the detection of
40 SARS-CoV-2 antibodies by standard ELISA. To test this, we first assessed the sensitivity and
41 specificity of two commercially available assays for serum (following manufacturers' instructions).
42 We then investigated multiple strategies for conversion of these assays for antibody detection in
43 saliva using clinical samples collected from RT-PCR-positive participants who were determined
44 to have antibodies as detected by serum testing.

45

46 We conclude that, when following our optimized protocol, it is possible to detect antibodies against
47 SARS-CoV-2 in saliva samples at a sensitivity of 84.2% and a specificity of 100% in the general
48 symptomatic population. If this population is limited to those over the age of 40, sensitivity of
49 91.5% and specificity of 100% is achievable.

50

51

52 Commercially available SARS-CoV-2 serum-based antibody detection ELISA kits from Gold
53 Standard Diagnostics (GSD) and EuroImmune (EI), which detect the nucleocapsid (N) and spike
54 (S) SARS-CoV-2 structural proteins respectively, were evaluated for their efficacy in detecting IgA
55 and IgG antibodies against the novel coronavirus (SARS-CoV-2) in clinical serum samples (**Fig.**
56 **1**). Due to uncertainty about which antibodies are most persistent over time⁵, kits for detecting
57 both IgA and IgG antibodies were evaluated. Kits for detecting IgM antibodies were also
58 considered, but due to a lack of consensus surrounding the persistence of IgM in blood¹⁶ we
59 chose to pursue IgG and IgA antibodies only. 76 serum samples collected prior to November 2019
60 (pre-SARS-CoV-2) were used as a negative control panel to evaluate specificity for both IgG and
61 IgA kits from each manufacturer. We determined that both GSD kits and the EI IgG kit were 100%
62 specific, while the EI IgA kit was 92% specific. We then also tested these kits for sensitivity against
63 clinical serum samples collected between April and July 2020.

64
65 Because of limited and confounding existing data on asymptomatic patients and the increased
66 sensitivity 21 days post-symptom onset reported by the ELISA manufacturers, we chose to only
67 investigate samples from symptomatic participants collected more than 21 days post-symptom
68 onset. We tested serum collected from 123 symptomatic, PCR-positive patients and from 83 PCR-
69 negative patients on both IgG and IgA ELISA kits from each manufacturer (**Fig. 1**). Based on the
70 virus positive patient samples, EI IgG and IgA kits were 90 and 86 percent sensitive respectively
71 and GSD IgG and IgA kits were 69 and 15 percent sensitive respectively based on cutoff values
72 for serum detection supplied by the manufacturers. Nine participants who had tested PCR-
73 negative for RNA derived from SARS-CoV-2 were positive for IgG antibodies against the virus
74 based on both EI and GSD antibody detection kits, suggesting that these patients were likely
75 infected by COVID-19 prior to their RT-PCR test (**Supp. Fig. 1**).

76

77 Our objective was to evaluate the ability of these tests to detect antibodies in saliva in addition to
78 detecting antibodies in serum samples. We selected the EI IgG kit for our saliva sample
79 optimization experiments based on its superior performance in our clinical serum sample testing.
80 All clinical study participants provided oral fluid for viral PCR testing and saliva and serum samples
81 for antibody testing. Saliva samples were collected using devices as described in the Methods
82 section. We selected saliva samples from COVID-19 positive participants (as determined by RT-
83 PCR) that were also positive for antibodies in serum, and samples from COVID-19 negative
84 participants (as determined by RT-PCR) that were also negative for antibodies in serum.
85 Comparing two different devices in a set of saliva samples (**Supp. Fig. 2**) showed that a
86 mouthwash (inhouse formulation, detailed in Methods section) yielded 100% sensitive and
87 specific results for antibody detection. Increasing our sample size to 50 positive and 33 negative
88 samples reduced the specificity to 93.6% and the sensitivity to 84.0% (AUC = 0.946) (**Fig. 2A**).
89 Based on this data, we further optimized the sample preparation and ELISA processes.
90 First, centrifuging the samples to remove a large pellet of mucin, a common practice among
91 studies of whole saliva samples^{12,17}, gave a sensitivity of 84.0% and specificity of 90.6% (AUC =
92 0.935). Second, the addition of a concentration step (Amicon Ultra Centrifugal Filters) improved
93 sensitivity to 84.4% and specificity to 95.8% (AUC = 0.962). Finally, blocking the ELISA plate with
94 a buffer containing TBS-Tween and 5% BSA for 30 minutes before adding sample yielded an
95 89.2% sensitivity and 96.3% specificity (AUC = 0.965) using a positivity cutoff of 0.40; this final
96 protocol yielded the best sensitivity and specificity for this set of mouthwash samples (**Fig. 2A**).
97
98 To determine whether the test remained sensitive and specific in an expanded population, we
99 applied this combined protocol (i.e. centrifugation, concentration, and blocking of the ELISA plate)
100 to a larger mouthwash sample group of 82 positive and 67 negative samples. In this population,
101 our test was 84.2% sensitive and 100% specific (AUC = 0.979) using a positivity threshold of 0.56

102 **(Fig. 2B)**. Antibody detection in saliva and serum showed a weak but statistically significant
103 correlation ($R=0.596$, $p<0.0001$). **(Fig. 2B)**.

104
105 Given our cohort of clinical samples (demographics in **Fig. 3A**), we wanted to determine if factors
106 linked to COVID-19 susceptibility impacted our sensitivity and specificity. By stratifying the data
107 based on patient demographics of age, sex, and days elapsed since onset of symptoms for
108 sample collection (**Supp. Table 1**), we found that testing samples only from those over 40 years
109 of age further improved our saliva-based antibody detection test (**Fig. 3B**). This sample set gave
110 a sensitivity of 91.5% and specificity of 100% (AUC = 0.989, **Fig. 3C**). This optimized test could
111 be used on populations of patients of 40 years or more of age, where we might suggest a
112 borderline range between IgG ratios of 0.40 and 0.55, and consider positive tests having an IgG
113 ratio greater than 0.56.

114
115 In conclusion, we have shown that testing for IgG against SARS-CoV2 is possible in saliva
116 samples, providing an easy, noninvasive option for detection of prior infection. Further
117 optimization and increasing the cohort size may improve this method to the levels recommended
118 by the FDA guidance (that is, better than 90% sensitivity and 100% specificity). Further work could
119 describe results in asymptomatic COVID-19 positive people, estimated to be as high as 40% of
120 cases¹⁸.

121
122 Development of this specific, sensitive antibody test from non-invasive samples which require no
123 exposure of healthcare workers to potentially infectious environments may be very valuable.
124 There is currently no documented reinfection in the US, which suggests immunity may be
125 protective on the order of months. Antibody testing could provide significant information for
126 countries interested in establishing the reach of the disease in order to help make policy decisions
127 about reopening towns, cities, and states.

128 **Methods**

129

130 Human serum and saliva sample collection.

131

132 *Pre-COVID-19 serum samples:* These samples were purchased from Cureline (Brisbane, CA),
133 and were collected before September 2019 from healthy adults in the USA.

134

135 *Post-COVID-19 serum and saliva samples*

136 Clinical samples were collected under UCLA Institutional Review Board approved study protocol
137 IRB#20-000703. The UCLA IRB determined the protocol was minimal risk and verbal informed
138 consent was sufficient for the research under 45 CFR 46.117(c)(2). The study team complied with
139 all UCLA policies and procedures, as well as with all applicable Federal, State, and local laws
140 regarding the protection of human subjects in research as stated in the approved IRB.

141

142 For this study, we worked with four specimens obtained: oral fluid for viral PCR testing, blood via
143 venipuncture, and two saliva specimens.

144 *Oral fluid swab for viral RNA:* This was obtained according to the reported guidelines for
145 Curative's oral fluid COVID-19 test. Briefly, participants coughed hard three times while shielding
146 their cough via mask and/or coughing into the crook of their elbow. They then swabbed the inside
147 of their cheeks, along the top and bottom gums, under the tongue, and finally on the tongue, to
148 gather a sufficient amount of saliva. Swabs were placed in a tube containing RNA shield and
149 transported at room temperature before laboratory processing as described¹⁹. Positive for viral
150 RNA was determined as below 35 cycle threshold (CT).

151 *Blood sampling:* Participants underwent a standard venipuncture procedure. Briefly,
152 licensed phlebotomists collected a maximum of 15ml whole blood into 3 red-top SST tubes
153 (Becton-Dickinson, cat. number 367988). Once collected, the sample was left at ambient

154 temperature for 30-60 minutes to coagulate, then was centrifuged at 2200-2500 rpm for 15
155 minutes at room temperature. Samples were then placed on ice until delivered to the laboratory
156 site where the serum was aliquoted to appropriate volumes for storage at -80 °C until use.

157 *Orasure saliva sample collection:* Orasure oral specimen collection devices (catalog
158 number 3001-2870, Orasure, USA) were used as instructed²⁰. The pad was brushed briefly on
159 the lower gums and then held between the gum and the cheek for 2-5 minutes. The pad was then
160 placed into the storage tube, with the provided storage solution. Samples were kept on ice until
161 they reached the lab. The samples were processed as recommended by the manufacturer²¹
162 before being aliquoted and stored at -80°C until use.

163 *Mouthwash saliva samples:* Mouthwash was made in-house by adding 3% Sodium
164 Chloride (15g), 0.2% Citric Acid (1g), 0.075% Sodium Benzoate (0.375g), 0.075% Potassium
165 Sorbate (0.375g) to 500mL of ddH₂O. The solution was then autoclaved (121°C for 20 minutes)
166 before pH adjustment to pH=6.5 with 0.1M of NaOH. 4ml aliquots were then used to vigorously
167 rinse the mouth for 1-2 minutes before being collected. Samples were kept on ice until they
168 reached the laboratory, where they were aliquoted (avoiding any large particulates in the liquid)
169 and stored at -80°C until use.

170

171

172 Serum ELISA

173

174 EuroImmune SARS-CoV-2 IgA and FDA EUA IgG ELISAs²² for serum (cat. numbers EI 2606-9620
175 IgA, EI 2606-9620 IgG, EuroImmune, New Jersey, USA) targeting spike (S) protein were run
176 according to the manufacturer provided protocol²³ on the Thunderbolt (Gold Standard
177 Diagnostics, Davis, CA) automated instrument. Briefly, serum was diluted 1:101 in each well with
178 the provided sample buffer and then incubated at 37°C for 1 hour. Sample wells were washed
179 three times with a provided wash buffer (10X dilution with ddH₂O, 0.35ml per well), before the

180 provided conjugate solution was added (0.1ml per well) and incubated at 37°C for 30 minutes.
181 After a second wash step, the provided substrate solution was added (0.1ml per well) and
182 incubated at ambient temperature for 30 minutes. The provided stop solution was then added
183 (0.1ml per well) and absorbance of sample wells measured immediately at 450 nm and 630 nm,
184 with output reports generated with optical density (O.D.) at 630nm subtracted from O.D. at 450nm.
185 Data were then analyzed as recommended by the manufacturer and results reported as a ratio
186 **(Equation 1)**.

187
188 **Equation 1.** Determination of sample absorbance ratio based on sample O.D. divided by the
189 averaged O.D. of the calibrators.

$$190 \quad \text{Ratio} = \frac{\text{O.D. of the control or clinical sample}}{\text{O.D. of the calibrator}}$$

191
192 Gold Standard SARS-CoV-2 IgG and IgA ELISAs for serum (cat. numbers GSD01-1029 IgA,
193 GSD01-1028 IgG, Gold Standard Diagnostics, Davis, USA) targeting nucleocapsid (N) protein
194 were run according to the manufacturer provided protocol on the Thunderbolt (Gold Standard
195 Diagnostics, Davis, CA) automated instrument. Briefly, serum was diluted 1:101 in each well with
196 the provided sample buffer and then incubated at room temperature for 30 minutes. Sample wells
197 were washed three times with a provided wash buffer (20X dilution with ddH₂O, 0.3ml per well),
198 before the provided conjugate solution was added (0.1 ml per well) and incubated at ambient
199 temperature for 30 minutes. After a second wash step, the provided substrate solution was added
200 (0.1ml per well) and incubated at ambient temperature for 30 minutes. The provided stop solution
201 was then added (0.05ml per well) and absorbance of sample wells measured immediately at 450
202 nm and 630 nm, with output reports generated with optical density (O.D.) 630nm subtracted from
203 O.D. at 450nm. Data were then analyzed as recommended based on a correction factor (specific
204 to each kit) and mathematical formula provided by the manufacturer (**Equation 2, 3**).

205

206 **Equation 2.** Determination of sample positivity cutoff value as an average of the calibrator values
207 multiplied by a lot specific correction factor.

$$208 \quad Cutoff = Correction\ Factor * \left(\frac{O.D.\cdot cal1 + O.D.\cdot cal2}{2} \right)$$

209

210 **Equation 3.** Determination of the antibody units as defined by the manufacturer by dividing
211 sample O.D. by the positivity cutoff value and multiplying by 10.

$$212 \quad Units = \left(\frac{Sample\ O.D.}{Cutoff} \right) * 10$$

213

214

215 Saliva ELISA optimizations

216

217 *Centrifugation of samples*

218 1ml of mouthwash samples were centrifuged at 15,000 rpm for 10 minutes (4°C). The supernatant
219 was then immediately transferred to a clean tube.

220

221 *Concentration of samples*

222 300ul of supernatant was placed in Amicon Ultra Centrifugal Filters (UFC5199BK, Millipore
223 Sigma, USA) and centrifuged at 4°C, 15,000rpm for 8 minutes. The concentrated sample was
224 then recovered via a second centrifugation step (4°C, 15,000 rpm for 5 minutes); this procedure
225 produced ~50ul of concentrated sample. 50ul of a blocking buffer prepared in house (5% BSA in
226 TBS with 0.5% Tween 20) was then added before the total volume (~100ul) was placed in each
227 well of the ELISA plate, and the protocol run as described above.

228

229 *Blocking of ELISA plate*

230 Prior to concentrated sample loading, 25uL of the in house blocking buffer (5% BSA in TBS with
231 0.5% Tween 20) was added to each well. Wells were incubated with a blocking buffer for 30
232 minutes at room temperature before adding sample to begin the ELISA.

233

234

235 Statistical analysis

236

237 ROC curves were generated in GraphPad Prism (GraphPad Prism Version 8.4.3, San Diego,
238 USA), with a 95% confidence interval. Area under the curves was also calculated. Correlation
239 between serum and saliva IgG values were calculated using a Pearson correlation computing R
240 between the two datasets, with a 95% confidence interval.

241

242 Data availability

243

244 The data that support the findings of this study are available from the authors upon reasonable
245 request.

246 **Acknowledgements**

247 The authors would like to thank Suzana Car, Joseph Kapcia III, Cedie Bagos, Aaron Angel,
248 Marilisa Santa-Cruz and Matthew Geluz.

249

250

251 **Author Contributions**

252 M.M and A.I. designed and ran experiments, analyzed and interpreted data, and drafted the
253 manuscript, K.T. analyzed and interpreted data and edited the manuscript, F.T., J.R.M., J.C. and
254 P.C. edited the manuscript, L.D., S.D, J.K., K.K., F.E.T., V.S. and L.M.L.P. designed experiments,
255 interpreted data, and drafted the manuscript, and F.E.T, V.S. and L.M.L.P conceptualized the
256 project.

257

258

259 **Competing interests**

260 All authors are, or were at the time of research, employed by Curative Inc, a COVID-19
261 diagnostics company. L.D., F.E.T. and V.S have partial ownership of Curative Inc.

References

1. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). (2020). Available at: <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>. (Accessed: 10th August 2020)
2. World Health Organization. Timeline of WHO's response to COVID-19. (2020). Available at: <https://www.who.int/news-room/detail/29-06-2020-covidtimeline>. (Accessed: 10th August 2020)
3. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. (2020). Available at: https://covid19.who.int/?gclid=EAlaIqobChMI36aMroyq6gIVUD2tBh2pewBmEAAAYASAAEgK65fD_BwE. (Accessed: 10th August 2020)
4. Holshue, M. L. *et al.* First Case of 2019 Novel Coronavirus in the United States. *N. Engl. J. Med.* **382**, 929–936 (2020).
5. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* (2020). doi:10.1038/s41591-020-0897-1
6. Our World in Data. Coronavirus (COVID-19) Testing. (2020). Available at: <https://ourworldindata.org/coronavirus-testing>. (Accessed: 10th August 2020)
7. CDC. Interim Guidelines for Clinical Specimens for COVID-19. (2020). Available at: <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#specimen>. (Accessed: 10th August 2020)
8. Mcdade, T. W. *et al.* Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community-and population-based screening. doi:10.1101/2020.04.28.20081844
9. Lange, B. *et al.* Dried blood spots as sample collection method for HCV antibody: a systematic review and meta-analysis. (2015).
10. Hodinka, R. L., Nagashunmugam, T. & Malamud, D. Detection of human immunodeficiency virus antibodies in oral fluids. *Clinical and Diagnostic Laboratory Immunology* **5**, 419–426 (1998).
11. Chohan, B. H. *et al.* Validation of a modified commercial enzyme-linked immunoassay for detection of human immunodeficiency virus type 1 immunoglobulin G antibodies in saliva. *Clin. Diagn. Lab. Immunol.* **8**, 346–348 (2001).
12. Hettegger, P. *et al.* High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology. (2019). doi:10.1371/journal.pone.0218456
13. Ceron, J. J. *et al.* Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A General Perspective. *J. Clin. Med.* **9**, 1491 (2020).
14. Han, P. & Ivanovski, S. Saliva-friend and foe in the COVID-19 outbreak. *Diagnostics* **10**, (2020).
15. Randad, P. R. *et al.* COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. *medRxiv Prepr. Serv. Heal. Sci.* (2020). doi:10.1101/2020.05.24.20112300
16. Sethuraman, N., Jeremiah, S. S. & Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA - Journal of the American Medical Association* **323**, 2249–2251 (2020).
17. Heaney, J. L. J., Phillips, A. C., Carroll, D. & Drayson, M. T. The utility of saliva for the assessment of anti-pneumococcal antibodies: investigation of saliva as a marker of antibody status in serum. *Biomarkers* **23**, 115–122 (2018).
18. Oran, D. P. & Topol, E. J. Prevalence of Asymptomatic SARS-CoV-2 Infection. *Ann. Intern. Med.* (2020). doi:10.7326/m20-3012
19. FDA. Curative Inc EUA. (2020). Available at:

- <https://www.fda.gov/media/137088/download>. (Accessed: 10th August 2020)
20. OraSure Technologies. OraSure® Oral Specimen Collection Device. Available at: <https://www.orasure.com/products-insurance/products-insurance-specimen.asp>. (Accessed: 10th August 2020)
21. OraSure Technologies. Oral Fluid Collection Device. Available at: <https://fda.report/GUDID/20608337000119>. (Accessed: 10th August 2020)
22. EuroImmun. Antibody detection tests for COVID-19 (ELISA). Available at: <https://www.coronavirus-diagnostics.com/antibody-detection-tests-for-covid-19.html>. (Accessed: 10th August 2020)
23. EuroImmun. *Anti-SARS-CoV-2 ELISA (IgG) Instruction for use*.

Figures




Figure 1. Detection of IgG or IgA antibodies against SARS-CoV-2 in serum samples collected prior to the spread of COVID-19 (pre-Nov. 2019), and people who previously tested negative (-) or positive (+) for COVID-19 using Curative's oral fluid PCR test. The positive cutoff values represented by the dotted lines were provided by the manufacturer. NC = negative control; PC = positive control




Figure 2. (A) Sample conditions tested for optimized detection of anti-SARS-CoV-2 antibodies in mouthwash saliva samples, in comparison to the original protocol (AUC=0.946); mucin removed (AUC=0.935), mucin removed and sample concentrated (AUC = 0.962), and mucin removed, sample concentrated, and non-specific binding blocked (AUC=0.965) (B) IgG was detected using the optimized protocol in a large sample set where positive and negative status was determined by both PCR and serum antibody status, providing 100% specificity with 84.2% sensitivity (AUC = 0.979). A Pearson correlation showed significant correlation between serum and saliva IgG ($R = 0.596$, $p < 0.0001$). Line of best fit is displayed with 95% confidence intervals.




Figure 3. (A) Visualization of the gender ($n = 149$), age ($n=149$), and days post symptom onset ($n = 85$) of our cohort of clinical samples. (B) Stratifying by age impacted the sensitivity and specificity of our optimized saliva protocol. (C) When limited to sampling people over 40 years of age, 91.5% sensitivity and 100% specificity (AUC = 0.988) can be achieved.